Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 6 | 2023 | 549 | 1.410 |
Why?
|
| Adenocarcinoma | 9 | 2023 | 1169 | 1.340 |
Why?
|
| Colorectal Neoplasms | 7 | 2023 | 938 | 1.340 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2022 | 106 | 1.070 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2022 | 21 | 0.950 |
Why?
|
| Lymphocytosis | 1 | 2022 | 10 | 0.880 |
Why?
|
| Gastritis | 1 | 2022 | 32 | 0.850 |
Why?
|
| Pathologists | 1 | 2021 | 24 | 0.770 |
Why?
|
| Lifting | 1 | 2020 | 12 | 0.750 |
Why?
|
| Smooth Muscle Tumor | 1 | 2020 | 4 | 0.740 |
Why?
|
| Barrett Esophagus | 1 | 2021 | 93 | 0.730 |
Why?
|
| Observer Variation | 1 | 2021 | 603 | 0.680 |
Why?
|
| Carcinogenesis | 3 | 2019 | 195 | 0.670 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2018 | 23 | 0.630 |
Why?
|
| Atrial Septum | 1 | 2017 | 9 | 0.610 |
Why?
|
| Lipomatosis | 1 | 2017 | 9 | 0.610 |
Why?
|
| Hamartoma | 1 | 2017 | 31 | 0.600 |
Why?
|
| Stomach Neoplasms | 4 | 2021 | 266 | 0.590 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2016 | 24 | 0.550 |
Why?
|
| Liver | 4 | 2022 | 1230 | 0.390 |
Why?
|
| Immunohistochemistry | 7 | 2021 | 1753 | 0.390 |
Why?
|
| Male | 22 | 2022 | 40988 | 0.360 |
Why?
|
| Aged | 16 | 2022 | 18423 | 0.350 |
Why?
|
| Humans | 34 | 2023 | 86678 | 0.350 |
Why?
|
| Esophageal Neoplasms | 3 | 2020 | 322 | 0.320 |
Why?
|
| Female | 20 | 2022 | 44550 | 0.310 |
Why?
|
| Middle Aged | 18 | 2023 | 25040 | 0.310 |
Why?
|
| Adult | 13 | 2022 | 25659 | 0.290 |
Why?
|
| Collagen | 3 | 2022 | 269 | 0.270 |
Why?
|
| Colitis | 2 | 2019 | 239 | 0.250 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 930 | 0.240 |
Why?
|
| Siderosis | 1 | 2023 | 2 | 0.230 |
Why?
|
| Iron Overload | 1 | 2023 | 6 | 0.230 |
Why?
|
| Diet, Western | 2 | 2023 | 37 | 0.230 |
Why?
|
| Hepatitis | 1 | 2023 | 35 | 0.230 |
Why?
|
| Colorectal Surgery | 1 | 2023 | 22 | 0.230 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2022 | 10 | 0.220 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2023 | 48 | 0.220 |
Why?
|
| Plasmacytoma | 1 | 2022 | 34 | 0.220 |
Why?
|
| Cytomegalovirus Infections | 1 | 2023 | 144 | 0.210 |
Why?
|
| Gastrointestinal Tract | 2 | 2022 | 191 | 0.210 |
Why?
|
| Aberrant Crypt Foci | 1 | 2022 | 7 | 0.210 |
Why?
|
| Goblet Cells | 1 | 2022 | 19 | 0.210 |
Why?
|
| Atrophy | 1 | 2022 | 117 | 0.210 |
Why?
|
| Adenomatoid Tumor | 1 | 2021 | 1 | 0.210 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 80 | 0.210 |
Why?
|
| Multiple Endocrine Neoplasia | 1 | 2021 | 7 | 0.210 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 6513 | 0.210 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2021 | 23 | 0.210 |
Why?
|
| Esophageal Stenosis | 1 | 2021 | 26 | 0.200 |
Why?
|
| Appendix | 1 | 2021 | 31 | 0.200 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 231 | 0.190 |
Why?
|
| Portal Vein | 1 | 2021 | 120 | 0.190 |
Why?
|
| Liver Cirrhosis | 2 | 2021 | 300 | 0.190 |
Why?
|
| Appendiceal Neoplasms | 1 | 2020 | 27 | 0.180 |
Why?
|
| Injections | 1 | 2020 | 109 | 0.180 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2020 | 19 | 0.180 |
Why?
|
| Surgical Stomas | 1 | 2020 | 22 | 0.180 |
Why?
|
| Buschke-Lowenstein Tumor | 1 | 2019 | 1 | 0.180 |
Why?
|
| Deglutition Disorders | 1 | 2021 | 115 | 0.180 |
Why?
|
| Fibrosis | 1 | 2021 | 203 | 0.180 |
Why?
|
| Mentors | 1 | 2021 | 76 | 0.180 |
Why?
|
| Hyperthermia, Induced | 1 | 2020 | 73 | 0.180 |
Why?
|
| Glutamate-Ammonia Ligase | 1 | 2019 | 10 | 0.180 |
Why?
|
| Cholangiocarcinoma | 1 | 2020 | 66 | 0.180 |
Why?
|
| Carcinoma in Situ | 1 | 2019 | 53 | 0.170 |
Why?
|
| Bile Duct Neoplasms | 1 | 2020 | 79 | 0.170 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2019 | 15 | 0.170 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2019 | 40 | 0.170 |
Why?
|
| Peritoneal Neoplasms | 1 | 2020 | 177 | 0.170 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 51 | 0.170 |
Why?
|
| Glucuronosyltransferase | 1 | 2020 | 184 | 0.160 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 307 | 0.160 |
Why?
|
| Colectomy | 1 | 2019 | 167 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 185 | 0.160 |
Why?
|
| Colitis, Lymphocytic | 1 | 2018 | 3 | 0.160 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 154 | 0.160 |
Why?
|
| Antidiarrheals | 1 | 2018 | 14 | 0.160 |
Why?
|
| Influenza, Human | 1 | 2021 | 329 | 0.160 |
Why?
|
| Anus Neoplasms | 1 | 2018 | 30 | 0.160 |
Why?
|
| Gene Amplification | 1 | 2018 | 131 | 0.150 |
Why?
|
| Cetuximab | 1 | 2018 | 113 | 0.150 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 526 | 0.150 |
Why?
|
| Hypertrophy | 1 | 2017 | 62 | 0.150 |
Why?
|
| Mesalamine | 1 | 2018 | 88 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1313 | 0.150 |
Why?
|
| Camptothecin | 1 | 2018 | 189 | 0.150 |
Why?
|
| Endoscopy | 1 | 2020 | 332 | 0.150 |
Why?
|
| Steroids | 1 | 2018 | 177 | 0.150 |
Why?
|
| Intestinal Mucosa | 1 | 2022 | 797 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 381 | 0.140 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 1056 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2017 | 295 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 2438 | 0.140 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2019 | 427 | 0.140 |
Why?
|
| Fatty Liver, Alcoholic | 1 | 2016 | 7 | 0.140 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2016 | 19 | 0.140 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2016 | 23 | 0.140 |
Why?
|
| Defecation | 1 | 2016 | 23 | 0.140 |
Why?
|
| Rectal Diseases | 1 | 2016 | 24 | 0.140 |
Why?
|
| Renin | 1 | 2016 | 79 | 0.140 |
Why?
|
| Choristoma | 1 | 2016 | 68 | 0.140 |
Why?
|
| Stomach | 1 | 2016 | 108 | 0.130 |
Why?
|
| Prognosis | 2 | 2020 | 3680 | 0.130 |
Why?
|
| Disease Progression | 1 | 2020 | 1532 | 0.130 |
Why?
|
| Renin-Angiotensin System | 1 | 2016 | 133 | 0.130 |
Why?
|
| Rectum | 1 | 2016 | 146 | 0.130 |
Why?
|
| Liver Transplantation | 1 | 2023 | 1271 | 0.130 |
Why?
|
| Diarrhea | 1 | 2016 | 182 | 0.130 |
Why?
|
| Pandemics | 1 | 2021 | 740 | 0.130 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 239 | 0.130 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 558 | 0.120 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 1464 | 0.120 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2019 | 456 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2017 | 395 | 0.110 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2016 | 212 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 1077 | 0.110 |
Why?
|
| Hyperplasia | 2 | 2023 | 148 | 0.110 |
Why?
|
| Comorbidity | 1 | 2016 | 944 | 0.110 |
Why?
|
| Genomics | 1 | 2017 | 720 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 386 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1566 | 0.100 |
Why?
|
| Young Adult | 2 | 2021 | 5980 | 0.100 |
Why?
|
| Adolescent | 2 | 2021 | 8984 | 0.100 |
Why?
|
| Retrospective Studies | 5 | 2023 | 8496 | 0.090 |
Why?
|
| Biopsy | 3 | 2021 | 1163 | 0.090 |
Why?
|
| Anastomosis, Surgical | 2 | 2023 | 267 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 738 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2020 | 7998 | 0.090 |
Why?
|
| Child | 1 | 2021 | 6928 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2019 | 2207 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 2 | 2023 | 1047 | 0.090 |
Why?
|
| Leucovorin | 2 | 2020 | 218 | 0.080 |
Why?
|
| Mutation | 1 | 2019 | 3968 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 266 | 0.070 |
Why?
|
| Fluorouracil | 2 | 2020 | 556 | 0.070 |
Why?
|
| Mice | 4 | 2023 | 11356 | 0.070 |
Why?
|
| Colon | 2 | 2021 | 496 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1807 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2023 | 2231 | 0.060 |
Why?
|
| Transferrins | 1 | 2023 | 3 | 0.060 |
Why?
|
| Ferritins | 1 | 2023 | 29 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2023 | 76 | 0.060 |
Why?
|
| Iron | 1 | 2023 | 164 | 0.050 |
Why?
|
| Allografts | 1 | 2023 | 172 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2020 | 2768 | 0.050 |
Why?
|
| Anastomotic Leak | 1 | 2023 | 96 | 0.050 |
Why?
|
| Esophagectomy | 1 | 2022 | 84 | 0.050 |
Why?
|
| Esophagoscopy | 1 | 2021 | 87 | 0.050 |
Why?
|
| Esophagus | 1 | 2021 | 102 | 0.050 |
Why?
|
| Autopsy | 1 | 2021 | 116 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2021 | 307 | 0.050 |
Why?
|
| Ostomy | 1 | 2020 | 15 | 0.050 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2020 | 73 | 0.050 |
Why?
|
| Animals | 4 | 2023 | 26590 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 418 | 0.050 |
Why?
|
| Seasons | 1 | 2021 | 223 | 0.040 |
Why?
|
| Organic Chemicals | 1 | 2019 | 33 | 0.040 |
Why?
|
| Enterococcus faecalis | 1 | 2019 | 46 | 0.040 |
Why?
|
| Interleukin-16 | 1 | 2019 | 7 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2023 | 512 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 332 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 235 | 0.040 |
Why?
|
| Bismuth | 1 | 2018 | 8 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 72 | 0.040 |
Why?
|
| Salicylates | 1 | 2018 | 25 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 56 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 329 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2018 | 94 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 674 | 0.040 |
Why?
|
| Remission Induction | 1 | 2019 | 722 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2019 | 506 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2023 | 1065 | 0.040 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 132 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1686 | 0.040 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2016 | 22 | 0.040 |
Why?
|
| Hydralazine | 1 | 2016 | 20 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 357 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 683 | 0.040 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 173 | 0.040 |
Why?
|
| Fumarates | 1 | 2016 | 26 | 0.040 |
Why?
|
| Losartan | 1 | 2016 | 42 | 0.040 |
Why?
|
| Survival Rate | 1 | 2020 | 1864 | 0.040 |
Why?
|
| Amides | 1 | 2016 | 60 | 0.040 |
Why?
|
| Intestines | 1 | 2019 | 411 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 2706 | 0.030 |
Why?
|
| Angiotensin II | 1 | 2016 | 95 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1380 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 816 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2016 | 80 | 0.030 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 90 | 0.030 |
Why?
|
| Smoking | 1 | 2019 | 609 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 301 | 0.030 |
Why?
|
| Endosonography | 1 | 2016 | 96 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 1204 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1852 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 1169 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2018 | 485 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 977 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1673 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 853 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 456 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 1992 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 747 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 1924 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2016 | 267 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2264 | 0.030 |
Why?
|
| Crohn Disease | 1 | 2020 | 730 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 1197 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 1718 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 1939 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 1540 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 3095 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 2426 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2016 | 669 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3642 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 1683 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 5420 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 4214 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 2360 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 3243 | 0.020 |
Why?
|
| United States | 1 | 2019 | 6681 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 1992 | 2262 | 0.010 |
Why?
|